Charles Schwab
FTH

Charles Schwab’s Faeth Therapeutics FTH Stock Holding History

Charles Schwab’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,193
Closed -$102K – 3634
2022
Q1 		$102K Hold
2,193
– – ﹤0.01% 3412
2021
Q4 		$255K Sell
2,193
-136
-6% -$20.3K ﹤0.01% 3316
2021
Q3 		$491K Sell
2,329
-419
-15% -$76.3K ﹤0.01% 3154
2021
Q2 		$537K Buy
2,748
+436
+19% +$108K ﹤0.01% 3149
2021
Q1 		$672K Buy
+2,312
New +$774K ﹤0.01% 2984

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's FTH Position: Q2 2022 in Review

Charles Schwab sold out of Faeth Therapeutics (FTH) in Q2 2022, closing a stake of 2,193 shares — an estimated $102K sold.

Charles Schwab first reported a position in FTH in Q1 2021 and held it in 5 quarters. The position peaked at $672K in Q1 2021. 39 funds tracked by Wall St. Rank hold FTH as of Q2 2022.

  • Charles Schwab reported no remaining Faeth Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 2,193 Faeth Therapeutics shares in Q2 2022, an estimated $102K.
  • Charles Schwab first reported a position in Faeth Therapeutics in Q1 2021 and held it in 5 quarters.
  • Charles Schwab's Faeth Therapeutics position peaked at $672K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.